Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$79.04 USD

79.04
640,484

-2.77 (-3.39%)

Updated Aug 5, 2024 10:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal

Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.

Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?

Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The Zacks Analyst Blog Highlights Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific

Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific are included in this Analyst Blog.

Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today

In the closing of the recent trading day, Astrazeneca (AZN) stood at $66.54, denoting a +0.03% change from the preceding trading day.

Sheraz Mian headshot

Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Procter & Gamble Company (PG) and AstraZeneca PLC (AZN).

Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Astrazeneca (AZN) closed the most recent trading day at $66.52, moving +0.41% from the previous trading session.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?

Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.

The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca

Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.

Astrazeneca (AZN) Laps the Stock Market: Here's Why

In the latest trading session, Astrazeneca (AZN) closed at $69.42, marking a +0.35% move from the previous day.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Kinjel Shah headshot

FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts

The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.

Here's Why Astrazeneca (AZN) Fell More Than Broader Market

Astrazeneca (AZN) closed at $69.18 in the latest trading session, marking a -0.56% move from the prior day.

AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Astrazeneca (AZN) settling at $68.38, representing a -0.58% change from its previous close.

Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs

Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals

Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.

Why the Market Dipped But Astrazeneca (AZN) Gained Today

Astrazeneca (AZN) reachead $68.78 at the closing of the latest trading day, reflecting a +0.67% change compared to its last close.

Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note

Astrazeneca (AZN) closed the most recent trading day at $67.35, moving +0.07% from the previous trading session.

Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday

Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.

Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Astrazeneca (AZN) closed at $67.35, indicating a +1.28% shift from the previous trading day.

AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.